PHLDB3

Across TCGA pan-cancer cohorts, PHLDB3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PHLDB3 data layer compared with 29 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PHLDB3 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated PHLDB3 expression acts as an unfavorable survival marker, although some lineages such as BLCA and OV show a favorable association.

BLCA, OV, and PRAD are the cancer types where PHLDB3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	II,III,IV	1.000	0.325	.016	22	view →
OV	DFS	Median	III,IV	1.000	0.366	.023	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.192	0.707	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PHLDB3–BLCA (DFS)

Open the BLCA breakdown →